Healthcare
•3755 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3755)
| Company | Market Cap | Price |
|---|---|---|
|
ATRA
Atara Biotherapeutics, Inc.
Atara focuses on tab-cel (Ebvallo), an allogeneic T-cell therapy.
|
$123.46M |
$17.70
+0.71%
|
|
LUCD
Lucid Diagnostics Inc.
EsoCheck is a diagnostic collection device used to obtain esophageal cells for testing, aligning with Diagnostic Equipment.
|
$122.58M |
$1.15
+1.33%
|
|
EHTH
eHealth, Inc.
eHealth's core business is to facilitate enrollment in health insurance products (Medicare and other plans).
|
$122.23M |
$4.00
-2.55%
|
|
FONR
FONAR Corporation
Core product offering is the Upright MRI hardware, a specialized medical imaging platform.
|
$122.17M |
$18.56
|
|
AVHHL
AVITA Medical, Inc.
AVITA Medical’s core offerings are wound care devices and dermal matrices (RECELL system, RECELL GO, PermeaDerm, Cohealyx) used in wound management, fitting the Wound Care Devices category.
|
$119.99M |
$0.79
|
|
CAMP
CAMP4 Therapeutics Corporation
Direct product category: oligonucleotide therapeutics (RNA Actuating Platform) using ASOs to upregulate gene expression.
|
$119.56M |
$6.04
-2.58%
|
|
ARTV
Artiva Biotherapeutics, Inc.
AlloNK AB-101 is an allogeneic NK cell therapy platform, constituting Artiva's core product line.
|
$118.59M |
$4.71
+2.95%
|
|
USGO
U.S. GoldMining Inc.
Metallurgical testwork and related lab analyses are conducted to inform processing and PEA.
|
$117.95M |
$9.30
+0.05%
|
|
FATE
Fate Therapeutics, Inc.
Fate develops oncology-focused immunotherapies, aligning with Biotech - Oncology.
|
$116.48M |
$1.01
|
|
LPTX
Leap Therapeutics, Inc.
Leap Therapeutics is a biotech company focused on oncology therapies, with lead assets in antibody-based cancer treatments.
|
$116.14M |
$2.04
+367.43%
|
|
IRD
Opus Genetics, Inc.
Core product area: AAV-based gene therapies for inherited retinal diseases (OPGx-LCA5, OPGx-BEST1).
|
$115.62M |
$1.95
-2.75%
|
|
VTVT
vTv Therapeutics Inc.
Cadisegliatin is an oral, small-molecule therapeutic developed by the company for Type 1 Diabetes, directly matching the 'Oral Small Molecule Therapeutics' category.
|
$113.65M |
$36.38
-11.39%
|
|
SERA
Sera Prognostics, Inc.
Direct Laboratory Testing & Advisory Services provided by SERA for the PreTRM test and related diagnostic offerings.
|
$113.42M |
$3.02
+1.34%
|
|
IPSC
Century Therapeutics, Inc.
Directly develops iPSC-derived cell therapies (CAR-iT, CAR-iNK, Allo-Evasion-enabled products) and related platforms.
|
$112.31M |
$1.76
+35.38%
|
|
NBY
NovaBay Pharmaceuticals, Inc.
Directly manufactures wound care devices which are the sole continuing reportable product line (export to China).
|
$111.58M |
$16.62
+75.69%
|
|
SEER
Seer, Inc.
SP100 instrument and related proteomics hardware qualify as Diagnostic Equipment.
|
$109.86M |
$1.92
+2.67%
|
|
MBOT
Microbot Medical Inc.
LIBERTY functions as a vascular/interventional device for endovascular surgery, aligning with Vascular Intervention Devices.
|
$109.77M |
$2.27
-6.02%
|
|
PYXS
Pyxis Oncology, Inc.
Pyxis Oncology is a biotechnology company focused on oncology therapeutics, with MICVO as its lead asset in cancer.
|
$109.15M |
$1.74
+19.66%
|
|
RPTX
Repare Therapeutics Inc.
Core company focus is oncology therapeutics with a synthetic lethality approach (Biotech - Oncology).
|
$109.12M |
$2.54
+0.40%
|
|
ANIX
Anixa Biosciences, Inc.
CER-T CAR-T therapy is a direct cell therapy product focused on oncology.
|
$108.87M |
$3.36
-1.75%
|
|
MGNX
MacroGenics, Inc.
Company develops bispecific antibody therapies via its DART platform, including lorigerlimab.
|
$108.71M |
$1.72
|
|
SLSN
Solesence, Inc. Common Stock
Solésence operates as a contract development and manufacturing organization (CDMO) for beauty products, matching Contract Manufacturing Organizations.
|
$106.43M |
$1.51
-1.31%
|
|
UNCY
Unicycive Therapeutics, Inc.
Lead programs Oxylanthanum Carbonate (OLC) and UNI-494 are oral small-molecule therapeutics targeting kidney disease and hyperphosphatemia/acute kidney injury.
|
$106.15M |
$6.21
+3.41%
|
|
ICAD
iCAD, Inc.
iCAD operates in the Medical Imaging domain, providing imaging software for breast health diagnostics.
|
$105.91M |
$3.87
|
|
GNLX
Genelux Corporation
Genelux focuses on oncology-focused viral immunotherapies, categorized under Biotech - Oncology.
|
$105.77M |
$2.75
+1.10%
|
|
ACOG
Alpha Cognition Inc. Common Stock
ZUNVEYL is Alpha Cognition's lead therapeutic targeting Alzheimer's disease.
|
$105.05M |
$6.50
+5.18%
|
|
HLVX
HilleVax, Inc.
Direct vaccine development activity with norovirus vaccine candidates (HIL-216.00) and existing vaccine focus.
|
$104.79M |
$2.09
|
|
STRO
Sutro Biopharma, Inc.
Directly represents Sutro's core assets: Antibody-Drug Conjugates (ADC) programs using the XpressCF+ platform.
|
$103.68M |
$13.09
+11.40%
|
|
CGTX
Cognition Therapeutics, Inc.
CT1812 (zervimesine) is an orally delivered small-molecule therapeutic, the core product of the company.
|
$103.60M |
$1.42
-1.05%
|
|
ELDN
Eledon Pharmaceuticals, Inc.
Tegoprubart is an IgG1 monoclonal antibody therapeutic targeting CD40L.
|
$103.60M |
$1.74
+0.29%
|
|
GUTS
Fractyl Health, Inc. Common Stock
Revita DMR System is a medical device used in outpatient endoscopic/metabolic procedures, representing a direct product Fractyl Health develops and sells.
|
$103.60M |
$2.02
-2.18%
|
|
CRBP
Corbus Pharmaceuticals Holdings, Inc.
Corbus's pipeline is focused on oncology assets (CRB-701 and CRB-601) representing biotech oncology products.
|
$101.84M |
$8.34
-0.24%
|
|
RANI
Rani Therapeutics Holdings, Inc.
RaniPill is the core drug-delivery platform enabling oral administration of biologics, central to the company's offering.
|
$100.62M |
$1.38
-1.08%
|
|
ARAY
Accuray Incorporated
Medical device components and subassemblies are part of device manufacturing for imaging/radiosurgery systems.
|
$99.63M |
$0.88
-0.60%
|
Showing page 25 of 38 (3755 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
